Dapagliflozin-citric acid cocrystal showing better solid state properties than dapagliflozin.

Citation data:

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, ISSN: 1879-0720, Vol: 104, Page: 255-261

Publication Year:
2017
Usage 11
Abstract Views 10
Link-outs 1
Captures 12
Readers 7
Exports-Saves 5
Citations 1
Citation Indexes 1
PMID:
28412482
DOI:
10.1016/j.ejps.2017.04.008
Author(s):
Deng, Jun-Hui, Lu, Tong-Bu, Sun, Changquan Calvin, Chen, Jia-Mei
Publisher(s):
Elsevier BV
Tags:
Pharmacology, Toxicology and Pharmaceutics
article description
Dapagliflozin (DAP) is a potent and selective sodium-glucose contransporter-2 inhibitor, for treating type 2 diabetes. DAP propanediol monohydrate (DAP-PDO-HO, 1:1:1) is the solid form used in the current tablet product to address the severe hygroscopicity problem of DAP free form. DAP-PDO-HO, however, suffers the problem of instability when exposed to high temperature, which renders it amorphous. In this work, we report on the preparation and evaluation of a new 1:1 cocrystal between DAP and citric acid (DAP-CA). The DAP-CA cocrystal exhibits superior stability against high temperature and high relative humidity without compromising dissolution and tableting performance. Thus, DAP-CA is a promising solid form for developing the next generation DAP tablet products with improved performance.

This article has 0 Wikipedia mention.